Free Trial

Lantheus (LNTH) Competitors

Lantheus logo
$86.45 +7.02 (+8.84%)
(As of 11/20/2024 ET)

LNTH vs. RIOT, NEOG, QDEL, CLDX, VIVO, TEVA, BGNE, VTRS, SMMT, and MRNA

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Riot Platforms (RIOT), Neogen (NEOG), QuidelOrtho (QDEL), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), and Moderna (MRNA).

Lantheus vs.

Riot Platforms (NASDAQ:RIOT) and Lantheus (NASDAQ:LNTH) are both mid-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.

40.3% of Riot Platforms shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 6.9% of Riot Platforms shares are held by insiders. Comparatively, 2.1% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Lantheus had 4 more articles in the media than Riot Platforms. MarketBeat recorded 7 mentions for Lantheus and 3 mentions for Riot Platforms. Lantheus' average media sentiment score of 1.02 beat Riot Platforms' score of 0.88 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Riot Platforms
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Lantheus
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Riot Platforms currently has a consensus target price of $16.35, indicating a potential upside of 34.57%. Lantheus has a consensus target price of $122.50, indicating a potential upside of 41.70%. Given Lantheus' higher possible upside, analysts plainly believe Lantheus is more favorable than Riot Platforms.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Riot Platforms
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.09
Lantheus
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Riot Platforms received 181 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 68.29% of users gave Riot Platforms an outperform vote while only 65.89% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
Riot PlatformsOutperform Votes
519
68.29%
Underperform Votes
241
31.71%
LantheusOutperform Votes
338
65.89%
Underperform Votes
175
34.11%

Lantheus has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Riot Platforms$312.91M12.90-$49.47M$1.518.05
Lantheus$1.30B4.64$326.66M$6.0114.38

Riot Platforms has a beta of 4.08, suggesting that its stock price is 308% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Riot Platforms has a net margin of 115.35% compared to Lantheus' net margin of 28.57%. Lantheus' return on equity of 44.29% beat Riot Platforms' return on equity.

Company Net Margins Return on Equity Return on Assets
Riot Platforms115.35% 14.89% 14.01%
Lantheus 28.57%44.29%23.52%

Summary

Lantheus beats Riot Platforms on 10 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$6.01B$2.52B$5.04B$8.81B
Dividend YieldN/A0.76%5.16%4.07%
P/E Ratio14.386.08130.5317.82
Price / Sales4.6430.871,183.8674.55
Price / Cash11.3916.3433.6132.53
Price / Book7.263.004.684.68
Net Income$326.66M$29.98M$119.23M$226.08M
7 Day Performance6.94%-1.26%-1.83%-1.04%
1 Month Performance-22.87%-9.92%-3.61%1.04%
1 Year Performance26.91%-14.62%31.74%26.28%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNTH
Lantheus
4.5262 of 5 stars
$86.45
+8.8%
$122.50
+41.7%
+25.1%$6.01B$1.30B14.38834Positive News
Gap Up
RIOT
Riot Platforms
4.1524 of 5 stars
$12.15
-1.0%
$16.35
+34.6%
+7.3%$4.08B$312.91M8.05340Insider Trade
Gap Up
NEOG
Neogen
2.153 of 5 stars
$14.90
-1.3%
$17.50
+17.4%
-8.5%$3.27B$924.22M0.002,640
QDEL
QuidelOrtho
4.5798 of 5 stars
$37.48
-2.9%
$58.83
+57.0%
-45.1%$2.59B$3.00B0.007,100Analyst Forecast
Gap Down
High Trading Volume
CLDX
Celldex Therapeutics
2.8776 of 5 stars
$26.40
+5.7%
$62.25
+135.8%
-3.0%$1.66B$6.88M0.00160Analyst Forecast
News Coverage
VIVO
Meridian Bioscience
1.0351 of 5 stars
$33.97
flat
N/AN/A$1.50B$333.02M35.02702Analyst Forecast
TEVA
Teva Pharmaceutical Industries
2.6924 of 5 stars
$17.03
+1.2%
$19.67
+15.5%
+80.0%$19.04B$15.85B0.0037,851
BGNE
BeiGene
3.174 of 5 stars
$194.26
+3.5%
$247.07
+27.2%
+3.4%$18.92B$2.46B-23.5810,600Analyst Downgrade
Gap Up
VTRS
Viatris
1.3448 of 5 stars
$13.13
+0.6%
$13.33
+1.5%
+38.6%$15.58B$15.43B0.0038,000
SMMT
Summit Therapeutics
1.863 of 5 stars
$18.62
-6.9%
$34.75
+86.6%
+835.7%$14.75B$700,000.000.00105Analyst Forecast
MRNA
Moderna
4.6267 of 5 stars
$36.94
-0.9%
$84.00
+127.4%
-53.2%$14.35B$6.85B0.005,600Analyst Upgrade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:LNTH) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners